izpis_h1_title_alt

Complete response in the axilla and the non-triple negative subtype are favourable prognostic factors for survival outcomes in inflammatory breast cancer
ID Grašič-Kuhar, Cvetka (Author), ID Borštnar, Simona (Author), ID Gazić, Barbara (Author), ID Matos, Erika (Author)

.pdfPDF - Presentation file, Download (2,77 MB)
MD5: D73B6843563671C8481256C5D8A6EAA2
URLURL - Source URL, Visit https://www.sciencedirect.com/science/article/pii/S0960977623000115 This link opens in a new window

Abstract
Aim: To assess real-world outcomes and prognostic factors of non-metastatic inflammatory breast cancer according to immunohistochemistry (IHC)-based subtype and treatment regimen. Methods: An institutional retrospective analysis of patients treated with neoadjuvant systemic treatment (NAST) for stage III inflammatory breast cancer diagnosed between 2001 and 2018 was performed. The survival outcomes in relation to patient characteristics, tumour characteristics, treatment modality and response to NAST were analyzed. Results: 225 patients fulfilled the inclusion criteria, 90% of patients were node-positive. IHC-based subtypes: 39.1% were HR+/HER2-, 19.1% HR+/HER2+, 23.1% HR-/HER2+ and 18.7% HR-/HER2-. Treatment was multimodal: NAST (100%), surgery (94.2%) and radiotherapy (94.2%). 53.3% of patients received adjuvant endocrine therapy, 34.3% (neo)adjuvant trastuzumab. Tri-modality therapy was applied in 89.3% of patients. Following NAST, a pathologic complete remission (pCR) in the breast was found in 16.9%, in the axilla in 29.7% and in both the breast and axilla in 10.3% of patients. The axillary pCR rate was significantly higher in HR-subtypes. Median overall survival (OS) was 8.9, 7.2, 5.8 and 2.3 years (p < 0.001) for HR+/HER2-, HR+/HER2+, HR-/HER2+ and HR-/HER2-subtype, respectively. On multivariate analysis, IHC-based subtype, age and axillary pCR were found as independent prognostic factors for RFS and OS. pCR rate and median OS improved over time, 5.8% vs 14.7% and 4.7 vs 10.0 years (2001–2009 vs. 2010–2018), respectively. Conclusions: Axillary pCR and the non-triple-negative IHC-based subtype are favourable prognostic factors for RFS and OS in inflammatory breast cancer. Introduction of taxanes and antiHER2 drugs contributed to improved pCR rate and OS.

Language:English
Keywords:inflammatory breast cancer, immunohistochemistry-based subtype, pathologic complete response, prognostic factors
Work type:Article
Typology:1.01 - Original Scientific Article
Organization:MF - Faculty of Medicine
Publication status:Published
Publication version:Version of Record
Year:2023
Number of pages:Str. 481-490
Numbering:Vol. 69
PID:20.500.12556/RUL-148281 This link opens in a new window
UDC:618.1
ISSN on article:1524-4741
DOI:10.1016/j.breast.2023.01.011 This link opens in a new window
COBISS.SI-ID:139958275 This link opens in a new window
Publication date in RUL:09.08.2023
Views:1252
Downloads:62
Metadata:XML DC-XML DC-RDF
:
Copy citation
Share:Bookmark and Share

Record is a part of a journal

Title:The breast journal
Shortened title:Breast j.
Publisher:Elsevier
ISSN:1524-4741
COBISS.SI-ID:519118617 This link opens in a new window

Licences

License:CC BY-NC-ND 4.0, Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International
Link:http://creativecommons.org/licenses/by-nc-nd/4.0/
Description:The most restrictive Creative Commons license. This only allows people to download and share the work for no commercial gain and for no other purposes.

Secondary language

Language:Slovenian
Keywords:rak dojke, pazduha, vnetni rak dojke, kemoterapija

Similar documents

Similar works from RUL:
Similar works from other Slovenian collections:

Back